Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.
Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.
In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.
Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.
With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.
ViiV Healthcare presented new real-world evidence and implementation data for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, at IDWeek 2024. Key findings include:
1. OPERA and Trio Health cohort studies showed >99% effectiveness in preventing HIV acquisition among nearly 1,300 individuals.
2. The PILLAR implementation study demonstrated reduced stigma and anxiety among 200 users compared to daily oral PrEP.
3. Trio Health cohort: Zero HIV diagnoses during follow-up, 83% persistence on CAB LA for PrEP injections.
4. OPERA study: 99.7% effectiveness, high adherence, and timely injections in a diverse U.S. cohort.
5. PILLAR study: Lower rates of PrEP stigma and anxiety, high acceptability, and convenience reported by users.
Pfizer (NYSE: PFE) announced FDA approval of HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents 12+ with hemophilia A or B without inhibitors. HYMPAVZI is the first anti-TFPI approved in the U.S. for hemophilia A or B treatment and the first to be administered via a pre-filled, auto-injector pen.
Key points:
- Once-weekly subcutaneous dosing
- 35% and 92% reduction in annualized bleeding rate compared to routine prophylaxis and on-demand treatment, respectively
- Common adverse reactions: injection site reactions, headache, and pruritus
- Approval based on Phase 3 BASIS trial results
This approval marks Pfizer's second hemophilia treatment approved by the FDA this year, following BEQVEZ™ for hemophilia B gene therapy.
Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE: PFE), has issued a letter to the company's Board of Directors expressing deep concern over recent events. The letter alleges that Pfizer representatives have threatened former executives Ian Read and Frank D'Amelio with litigation, compensation clawbacks, and cancellation of unvested stock units unless they publicly support current CEO Dr. Albert Bourla.
Starboard views this as coercive conduct and a breach of fiduciary duty. They are calling for the Board to establish a special committee to investigate and hold responsible parties accountable. Despite these concerns, Starboard remains committed to constructive engagement with Pfizer and looks forward to an upcoming meeting to discuss the company's path forward.
Pfizer Inc. (NYSE: PFE) announced positive topline results from the final overall survival (OS) analysis of the TALAPRO-2 study. The study evaluated TALZENNA® (talazoparib), an oral PARP inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Results showed a statistically significant and clinically meaningful improvement in OS for all patients and those with homologous recombination repair (HRR) gene-mutated mCRPC, compared to XTANDI alone. This makes TALZENNA plus XTANDI the first and only PARP inhibitor-ARPI combination to significantly improve survival in mCRPC patients, regardless of mutation status.
The safety profile was consistent with known profiles of each medicine. Detailed results will be presented at an upcoming medical congress and shared with global health authorities for potential label updates.
Pfizer Inc. (NYSE: PFE) has announced that its board of directors has declared a $0.42 fourth-quarter 2024 dividend on the company's common stock. The dividend will be payable on December 2, 2024, to shareholders of record at the close of business on November 8, 2024. This marks Pfizer's 344th consecutive quarterly dividend, highlighting the company's commitment to returning value to shareholders.
Pfizer, a global biopharmaceutical company, focuses on developing innovative medicines and vaccines to improve people's lives. With a 175-year history, Pfizer strives to set industry standards in quality, safety, and value in healthcare product development. The company collaborates with various stakeholders to expand access to affordable healthcare worldwide.
Pfizer Inc. (NYSE: PFE) will present 49 abstracts from company- and collaborator-led studies at IDWeek 2024 in Los Angeles from October 16-19, 2024. The presentations will showcase advancements in Pfizer's infectious disease portfolio, covering RSV, COVID-19, pneumococcal disease, Lyme disease, meningococcal disease, and serious bacterial and fungal infections.
Key highlights include:
- Pharmacokinetics and safety of nirmatrelvir/ritonavir in pediatric COVID-19 patients
- Real-world effectiveness of Abrysvo vaccine against RSV-related hospitalizations
- Safety and immunogenicity of coadministered COVID-19 and RSV vaccines
- Effectiveness of COVID-19 vaccination against long COVID in older adults
- Updates on Lyme disease vaccine candidate VLA15
- Epidemiology of invasive meningococcal disease in the US
- Impact of pneumococcal conjugate vaccines on vaccine serotypes
ViiV Healthcare, majority owned by GSK with Pfizer and Shionogi as shareholders, has committed to making at least two million doses of long-acting cabotegravir for HIV pre-exposure prophylaxis (CAB LA for PrEP) available for low- and middle-income countries (L&MICs) during 2025-2026. This triples the company's available supply compared to 2024, aiming to accelerate access where HIV burden is highest.
The rollout of CAB LA for PrEP is progressing rapidly in Sub-Saharan Africa and lower income countries, with half of the approvals to date in Sub-Saharan Africa and 79% in L&MICs. ViiV is providing the product at a not-for-profit price for low-income and Sub-Saharan African countries. By the end of 2024, ViiV will have supplied CAB LA for PrEP to partners for rollout in 14 countries.
ViiV is also working with generic manufacturers through a licensing agreement with the Medicines Patent Pool to develop generic formulations, aiming to improve affordability and expand capacity in resource- settings.
Pfizer Inc. (NYSE: PFE) has announced the voluntary withdrawal of OXBRYTA® (voxelotor), a treatment for sickle cell disease (SCD), from all worldwide markets where it is approved. The company is also discontinuing all active voxelotor clinical trials and expanded access programs globally. This decision is based on clinical data indicating that the overall benefit of OXBRYTA no longer outweighs the risks in the approved SCD patient population.
The data suggests an imbalance in vaso-occlusive crises and fatal events, which require further assessment. Pfizer has notified regulatory authorities about these findings and is advising patients to contact their physicians to discuss alternative treatments. The company will continue to investigate the findings and keep stakeholders informed about next steps for OXBRYTA.
Pfizer does not anticipate that this event will impact its full-year 2024 financial guidance.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for October 29, 2024, at 10:00 a.m. EDT. The call aims to provide an update on Pfizer's Third Quarter 2024 Performance Report, which will be released that morning. Investors and the public can access the webcast and report at www.pfizer.com/investors.
Participants can join via webcast or by dialing 800-456-4352 (US/Canada) or 785-424-1086 (international) with passcode '72940'. A transcript and replay will be available on Pfizer's website within 24 hours after the call, accessible for at least 90 days.
Pfizer, a leading biopharmaceutical company, focuses on developing innovative medicines and vaccines to improve lives globally. With a 175-year history, Pfizer collaborates with healthcare providers and communities to advance wellness and expand access to affordable healthcare worldwide.
Pfizer (NYSE: PFE) announced positive results from its Phase 2 study of ponsegromab, a monoclonal antibody targeting GDF-15, for cancer cachexia. The study met its primary endpoint, showing significant body weight increases compared to placebo across all doses, with a 5.61% mean increase at the highest dose after 12 weeks. Ponsegromab was generally safe and well-tolerated.
At the highest dose, improvements were observed in appetite, cachexia symptoms, physical activity, and muscle mass. Based on these promising results, Pfizer plans to initiate registration-enabling studies in 2025. The study included 187 participants with non-small cell lung, pancreatic, or colorectal cancer. Ponsegromab is also being investigated for heart failure patients with elevated GDF-15 levels.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
What is Pfizer Inc. known for?
Where is Pfizer's headquarters located?
How much does Pfizer make annually?
What are some of Pfizer's top-selling products?
What is the significance of Pfizer's international sales?
What recent collaborations has Pfizer been involved in?
When was Pfizer founded?
What is Pfizer's approach to innovation?
How does Pfizer contribute to cancer treatment?
What role do strategic partnerships play for Pfizer?
